[1]
|
Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Friedlaender, A., et al. (2020) Targeted Therapies in Early Stage NSCLC: Hype or Hope? International Journal of Molecular Sciences, 21, Article No. 6329. https://doi.org/10.3390/ijms21176329
|
[3]
|
Li, J., Zhu, H., Sun, L., Xu, W. and Wang, X. (2019) Prognostic Value of Site-Specific Metastases in Lung Cancer: A Population Based Study. Journal of Cancer, 10, 3079-3086. https://doi.org/10.7150/jca.30463
|
[4]
|
Yu, J., et al. (2021) Liver Metastasis Restrains Immunotherapy Efficacy via Macrophage-Mediated T Cell Elimination. Nature Medicine, 27, 152-164. https://doi.org/10.1038/s41591-020-1131-x
|
[5]
|
Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications, 42, 937-970. https://doi.org/10.1002/cac2.12359
|
[6]
|
Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249. https://doi.org/10.1146/annurev-pathol-042020-042741
|
[7]
|
Borghaei, H., et al. (2021) Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733. https://doi.org/10.1200/JCO.20.01605
|
[8]
|
Borghaei, H., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 1627-1639. https://doi.org/10.1056/NEJMoa1507643
|
[9]
|
Brahmer, J., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
|
[10]
|
Xie, M., et al. (2022) The Efficacy of PD-1/PD-L1 Inhibitors in Pa-tients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study. Cancers, 14, Article No. 4333. https://doi.org/10.3390/cancers14174333
|
[11]
|
Hong, L., et al. (2023) Efficacy and Clinicogenomic Correlates of Response to Immune Checkpoint Inhibitors Alone or with Chemotherapy in Non-Small Cell Lung Cancer. Nature Communications, 14, Article No. 695.
https://doi.org/10.1038/s41467-023-36328-z
|
[12]
|
Li, L., et al. (2020) Indirect Comparison betweenImmunotherapy Alone and Immunotherapy plus Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Systematic Review. BMJ Open, 10, e034010.
https://doi.org/10.1136/bmjopen-2019-034010
|
[13]
|
Choi, M.G., et al. (2021) Different Prognostic Implications of Hepatic Metastasis According to Front-Line Treatment in Non-Small Cell Lung Cancer: A Real-World Retrospective Study. Translational Lung Cancer Research, 10, 2551-2561.
https://doi.org/10.21037/tlcr-21-206
|
[14]
|
Zhu, Z., et al. (2022) International Consensus on Radiotherapy in Meta-static Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 11, 1763-1795. https://doi.org/10.21037/tlcr-22-644
|
[15]
|
Corrao, G., et al. (2020) Stereotatic Radiotherapy in Metastatic Non-Small Cell Lung Cancer: Combining Immunotherapy and Radiotherapy with a Focus on Liver Metastases. Lung Cancer, 142, 70-79.
https://doi.org/10.1016/j.lungcan.2020.02.017
|
[16]
|
Spigel, D.R., et al. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311.
https://doi.org/10.1200/JCO.21.01308
|
[17]
|
Wujanto, C., et al. (2019) Stereotactic Body Radiotherapy for Oli-gometastatic Disease in Non-Small Cell Lung Cancer. Frontiers in Oncology, 9, Article 1219. https://doi.org/10.3389/fonc.2019.01219
|
[18]
|
Vanneste, B.G.L., Van Limbergen, E.J., Reynders, K. and De Ruysscher, D. (2021) An Overview of the Published and Running Randomized Phase 3 Clinical Results of Radiotherapy in Combination with Immunotherapy. Translational Lung Cancer Research, 10, 2048-2058. https://doi.org/10.21037/tlcr-20-304
|
[19]
|
Ettinger, D.S., et al. (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 497-530. https://doi.org/10.6004/jnccn.2022.0025
|
[20]
|
Arbour, K.C. and Riely, G.J. (2019) Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA, 322, 764-774. https://doi.org/10.1001/jama.2019.11058
|
[21]
|
Ren, S., Xiong, X., You, H., Shen, J. and Zhou, P. (2021) The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 12, Article 689132. https://doi.org/10.3389/fimmu.2021.689132
|
[22]
|
Moya-Horno, I., Viteri, S., Karachaliou, N. and Rosell, R. (2018) Combination of Immunotherapy with Targeted Therapies in Advanced Non-Small Cell Lung Cancer (NSCLC). Thera-peutic Advances in Medical Oncology, 10.
https://doi.org/10.1177/1758834017745012
|
[23]
|
Reck, M., et al. (2019) Atezolizumab plus Bevacizumab and Chemotherapy in Non-Small-Cell Lung Cancer (IMpower150): Key Subgroup Analyses of Patients with EGFR Muta-tions or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. The Lancet Respiratory Medicine, 7, 387-401.
https://doi.org/10.1016/S2213-2600(19)30084-0
|
[24]
|
Herbst, R.S., et al. (2016) Pembrolizumab versus Docet-axel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled. Lancet, 387, 1540-1550.
https://doi.org/10.1016/S0140-6736(15)01281-7
|
[25]
|
Chae, Y.K., et al. (2018) Current Landscape and Future of Dual Anti-CTLA4 and PD-1/PD-L1 Blockade Immunotherapy in Cancer; Lessons Learned from Clinical Trials with Melanoma and Non-Small Cell Lung Cancer (NSCLC). Journal for ImmunoTherapy of Cancer, 6, Article No. 39. https://doi.org/10.1186/s40425-018-0349-3
|
[26]
|
Hellmann, M.D., et al. (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal of Medicine, 378, 2093-2104. https://doi.org/10.1056/NEJMoa1801946
|
[27]
|
Antonia, S., et al. (2016) Safety and Antitumour Activity of Dur-valumab plus Tremelimumab in Non-Small Cell Lung Cancer: A Multicentre, Phase 1b Study. The Lancet Oncology, 17, 299-308.
https://doi.org/10.1016/S1470-2045(15)00544-6
|
[28]
|
Hellmann, M.D., et al. (2017) Nivolumab plus Ipilimumab as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer (CheckMate 012): Results of an Open-Label, Phase 1, Multicohort Study. The Lancet Oncology, 18, 31-41. https://doi.org/10.1016/S1470-2045(16)30624-6
|
[29]
|
Paz-Ares, L.G., et al. (2022) First-Line Nivolumab plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes from the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17, 289-308.
https://doi.org/10.1016/j.jtho.2021.09.010
|
[30]
|
Puri, S. and Shafique, M. (2020) Combination Checkpoint Inhibi-tors for Treatment of Non-Small-Cell Lung Cancer: An Update on Dual Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies. Drugs in Context, 9, Article ID: 2019-9-2.
https://doi.org/10.7573/dic.2019-9-2
|
[31]
|
Brito, A.B.C., Camandaroba, M.P.G. and de Lima, V.C.C. (2021) An-ti-PD1 versus Anti-PD-L1 Immunotherapy in First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Sys-tematic Review and Meta-Analysis. Thoracic Cancer, 12, 1058-1066. https://doi.org/10.1111/1759-7714.13867
|
[32]
|
Qin, B.-D., et al. (2020) The Effect of Liver Metastasis on Efficacy of Immunotherapy plus Chemotherapy in Advanced Lung Cancer. Critical Reviews in Oncology/Hematology, 147, Arti-cle ID: 102893.
https://doi.org/10.1016/j.critrevonc.2020.102893
|
[33]
|
Liu, J., Li, C., Seery, S., Yu, J. and Meng, X. (2020) Identi-fying Optimal First-Line Interventions for Advanced Non-Small Cell Lung Carcinoma According to PD-L1 Expression: A Systematic Review and Network Meta-Analysis. OncoImmunology, 9, Article 1746112. https://doi.org/10.1080/2162402X.2020.1746112
|
[34]
|
Liang, H., et al. (2020) Feasibility and Safety of PD-1/L1 Inhibitors for Non-Small Cell Lung Cancer in Front-Line Treatment: A Bayesian Network Meta-Analysis. Translational Lung Cancer Research, 9, 188-203.
https://doi.org/10.21037/tlcr.2020.02.14
|
[35]
|
Ishige, F., et al. (2018) Hepatectomy for Oligo-Recurrence of Non-Small Cell Lung Cancer in the Liver. International Journal of Clinical Oncology, 23, 647-651. https://doi.org/10.1007/s10147-018-1262-y
|
[36]
|
Hakoda, H., et al. (2019) Hepatectomy for Rapidly Growing Sol-itary Liver Metastasis from Non-Small Cell Lung Cancer: A Case Report. Surgical Case Reports, 5, Article No. 71. https://doi.org/10.1186/s40792-019-0633-6
|
[37]
|
Nagashima, A., Abe, Y., Yamada, S., Nakagawa, M. and Yoshi-matsu, T. (2004) Long-Term Survival after Surgical Resection of Liver Metastasis from Lung Cancer. The Japanese Journal of Thoracic and Cardiovascular Surgery, 52, 311-313. https://doi.org/10.1007/s11748-004-0050-y
|
[38]
|
Ileana, E., Greillier, L., Moutardier, V. and Barlesi, F. (2010) Sur-gical Resection of Liver Non-Small Cell Lung Cancer Metastasis: A Dual Weapon? Lung Cancer, 70, 221-222. https://doi.org/10.1016/j.lungcan.2010.08.010
|
[39]
|
Takahashi, H. and Berber, E. (2020) Role of Thermal Abla-tion in the Management of Colorectal Liver Metastasis. Hepatobiliary Surgery and Nutrition, 9, 49-58. https://doi.org/10.21037/hbsn.2019.06.08
|
[40]
|
Martins, F., et al. (2019) Adverse Effects of Im-mune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nature Reviews Clinical Oncology, 16, 563-580. https://doi.org/10.1038/s41571-019-0218-0
|